<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Lipid Res</journal-id><journal-id journal-id-type="iso-abbrev">J. Lipid Res</journal-id><journal-id journal-id-type="publisher-id">jlr</journal-id><journal-title-group><journal-title>Journal of Lipid Research</journal-title></journal-title-group><issn pub-type="ppub">0022-2275</issn><issn pub-type="epub">1539-7262</issn><publisher><publisher-name>The American Society for Biochemistry and Molecular
Biology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22892157</article-id><article-id pub-id-type="pmc">3466011</article-id><article-id pub-id-type="publisher-id">p022392</article-id><article-id pub-id-type="doi">10.1194/jlr.P022392</article-id><article-categories><subj-group subj-group-type="heading"><subject>Patient-Oriented and Epidemiological Research</subject></subj-group></article-categories><title-group><article-title>Effects of prescription niacin and omega-3 fatty acids on lipids and
vascular function in metabolic syndrome: a randomized controlled trial<xref ref-type="fn" rid="fn1">[S]</xref></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Shearer</surname><given-names>Gregory C.</given-names></name><xref ref-type="corresp" rid="cor1"><sup>1</sup></xref><xref ref-type="aff" rid="aff1">*</xref><xref ref-type="aff" rid="aff2">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Pottala</surname><given-names>James V.</given-names></name><xref ref-type="aff" rid="aff1">*</xref></contrib><contrib contrib-type="author"><name><surname>Hansen</surname><given-names>Susan N.</given-names></name><xref ref-type="aff" rid="aff1">*</xref></contrib><contrib contrib-type="author"><name><surname>Brandenburg</surname><given-names>Verdayne</given-names></name><xref ref-type="aff" rid="aff1">*</xref><xref ref-type="aff" rid="aff2">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Harris</surname><given-names>William S.</given-names></name><xref ref-type="aff" rid="aff1">*</xref><xref ref-type="aff" rid="aff2">&#x02020;</xref></contrib><aff id="aff1"><label>*</label>Sanford Research/USD, <institution>University of
South Dakota</institution>, Sioux Falls, <addr-line>SD</addr-line>, and</aff><aff id="aff2"><label>&#x02020;</label>Sanford School of Medicine,
<institution>University of South Dakota</institution>, Sioux Falls,
<addr-line>SD</addr-line></aff></contrib-group><author-notes><fn><p>Clinical trial registration: <ext-link ext-link-type="uri" xlink:href="clinicaltrials.gov">clinicaltrials.gov</ext-link> (NCT00286234).</p></fn><corresp id="cor1"><label>1</label>To whom correspondence should be addressed. e-mail:
<email xlink:type="simple">greg.shearer@sanfordhealth.org</email></corresp></author-notes><pub-date pub-type="epub-ppub"><month>11</month><year>2012</year></pub-date><!--Fake ppub date generated  by PMC from publisher pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><month>11</month><year>2012</year></pub-date><volume>53</volume><issue>11</issue><fpage>2429</fpage><lpage>2435</lpage><history><date date-type="received"><day>10</day><month>11</month><year>2011</year></date><date date-type="rev-recd"><day>10</day><month>7</month><year>2012</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2012 by the American Society for Biochemistry and
Molecular Biology, Inc.</copyright-statement><copyright-year>2012</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p><bold>Author's Choice</bold>&#x02014;Final version full
access.</license-p><license-p><ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">Creative Commons
Attribution Non-Commercial License</ext-link> applies to Author Choice
Articles</license-p></license></permissions><abstract><p>The metabolic syndrome includes both dyslipidemia and impaired vascular function.
Because extended-release niacin (ERN) and prescription omega-3 acid ethyl-esters
(P-OM3) independently improve these characteristics, we tested their effects in
combination. Sixty metabolic syndrome subjects were randomized to 16 weeks of
treatment on dual placebo, P-OM3 (4g/day), ERN (2 g/day), or combination in a
double-blind trial. Lipoprotein subfractions and vascular endpoints were measured and
tested using ANCOVA. ERN increased HDL cholesterol by 5.4 mg/dl from baseline
(<italic>P</italic> = 0.04), decreased triglycerides (TG) by 39 mg/dl
(&#x02212;21%, <italic>P</italic> = 0.003), and decreased the augmentation
index, which is a measure of vascular stiffness, by 3.5 units (<italic>P</italic>
= 0.04). P-OM3 reduced TG by 26 mg/dl (&#x02212;13%, <italic>P</italic> =
0.04). Combination treatment increased HDL cholesterol by 7.8 mg/dl
(<italic>P</italic> = 002) and decreased TG by 72 mg/dl (&#x02212;34%) but
there was no improvement in vascular stiffness. Detailed analysis of lipoprotein
subfractions revealed increased large, bouyant HDL<sub>2</sub> (3.3 mg/dl;
<italic>P</italic> = 0.002) and decreased VLDL<sub>1+2</sub>
(&#x02212;32%; <italic>P</italic> &#x0003c; 0.0001), among subjects treated with combination
therapy, that were not present with either therapy alone. ERN and P-OM3 alone
improved characteristics of metabolic syndrome; however, whereas subjects on
combination therapy did not have improved vascular stiffness, TG and HDL levels
improved as did certain lipoprotein subfractions.</p></abstract><kwd-group><kwd>fish oil</kwd><kwd>niacin</kwd><kwd>metabolic syndrome</kwd><kwd>very low density lipoprotein</kwd><kwd>high density lipoprotein</kwd><kwd>arterial stiffness</kwd><kwd>augmentation index</kwd><kwd>eicosapentaenoic acid</kwd><kwd>docosahexaenoic acid</kwd></kwd-group></article-meta></front><body><p>The metabolic syndrome afflicts approximately 25% of the US adult population (<xref ref-type="bibr" rid="bib1">1</xref>) with a similar prevalence in other populations in
rough proportion to their degree of &#x02018;Westernization&#x02019;. Subjects with metabolic
syndrome are at increased risk for stroke (<xref ref-type="bibr" rid="bib2">2</xref>),
coronary heart disease (CHD)-death, and death from any cause (<xref ref-type="bibr" rid="bib3">3</xref>, <xref ref-type="bibr" rid="bib4">4</xref>). Metabolic syndrome is
defined by central obesity, elevated triglyceride (TG) levels, decreased HDL cholesterol
(HDL-C) levels, and mild elevations of glucose and blood pressure; numerous physiologic
dysfunctions contribute to the overall pathology. For instance, elevated blood pressure is
thought to be the result of dysfunctional endothelium-dependent vasodilation and
progressive arterial stiffening (<xref ref-type="bibr" rid="bib5">5</xref>). Also
associated with the metabolic syndrome is a preponderance of small, dense LDL particles
(<xref ref-type="bibr" rid="bib6">6</xref>) and an increased thrombotic tendency (<xref ref-type="bibr" rid="bib7">7</xref>). Although lifestyle changes (diet and exercise) can
improve many of these conditions, pharmacotherapy is often needed to normalize individual
components.</p><p>Because metabolic syndrome is comprised of multiple relatively mild disturbances instead of
a single overt pathology, the best therapeutic strategy for managing it is still emerging.
Elevated TG and reduced HDL are two of the three most prevalent factors in both younger men
and women, and elevated TG is a primary contributor to the overall risk (<xref ref-type="bibr" rid="bib8">8</xref>). The ideal intervention would safely and
effectively address as many of the components of the syndrome as possible.</p><p>Niacin reduces serum TG and LDL-C and raises HDL-C (<xref ref-type="bibr" rid="bib9">9</xref>). Further, niacin has been shown to reverse atherosclerosis (<xref ref-type="bibr" rid="bib10">10</xref>) and reduce risk for CHD and mortality (<xref ref-type="bibr" rid="bib11">11</xref>) [although the AIM-HIGH trial with niacin was
stopped early for inefficacy (<xref ref-type="bibr" rid="bib12">12</xref>)] Prescription
omega-3 acid ethyl esters (P-OM3) are also effective in reducing serum TG (<xref ref-type="bibr" rid="bib13">13</xref>, <xref ref-type="bibr" rid="bib14">14</xref>) and
have been shown to reduce risk and improve survival in the setting of CHD (<xref ref-type="bibr" rid="bib15">15</xref>&#x02013;<xref ref-type="bibr" rid="bib17">17</xref>). Both agents have also been reported to improve vascular function (<xref ref-type="bibr" rid="bib18">18</xref>, <xref ref-type="bibr" rid="bib19">19</xref>).
Here, we sought to measure the effects of these two agents, separately and in combination,
on lipid risk parameters and markers of vascular disease (e.g., endothelial dysfunction and
arterial stiffness) in metabolic syndrome patients.</p><sec sec-type="methods"><title>METHODS</title><sec><title>Participants and study location</title><p>The study was conducted at Sanford Research/USD in cooperation with Sanford
Clinic&#x02013;Clinical Research Services in Sioux Falls, South Dakota. Subjects with
metabolic syndrome were recruited by advertisements and from booths at local health
fairs. Those expressing interest in participation were screened by a phone interview,
and qualifiers were asked to attend a screening visit where informed consent was
obtained. Blood pressure, morphometry, and a lipid panel were collected. Inclusion
criteria were: age 40 to 69 years; BMI 25 to 40 kg/m<sup>2</sup>; fasting TG, 150 to
750 mg/dl; HDL-C &#x0003e; 10 mg/dl; and the ratio of TG/HDL-C &#x0003e; 3.5. Exclusion
criteria included: presence of other secondary causes of dyslipidemia or
hyperglycemia such as hepatic, renal, thyroid, or other endocrine diseases; history
of hypersensitivity to niacin or fish oils; history of gout, hepatitis, peptic ulcer,
or cardiovascular disease; presence of diabetes mellitus; use of any dietary
supplements providing more than 50 mg of niacin or 100 mg of fish oil omega-3 fatty
acids (n-3 FAs); use of any herbal preparations or weight-loss products; use of any
lipid-lowering drugs (other than statins) for at least four weeks prior to screening
for the study; medically-required treatment with nitrates, calcium channel blockers,
or adrenergic blocking agents; hemoglobin &#x0003c; 12 g/dl; LDL-C &#x0003e; 145 mg/dl; or
known substance abuse. The protocol was approved by the Institutional Review Board at
the University of South Dakota and informed consent was required prior to
participation. The study was registered at clinicaltrials.gov (NCT00286234).</p></sec><sec><title>Study design</title><p>This was a randomized, double-blind, placebo-controlled clinical trial with a 2
&#x000d7; 2 factorial treatment design (<xref ref-type="fig" rid="fig1">Fig. 1</xref>).
Group size was determined from a pilot study (<xref ref-type="bibr" rid="bib20">20</xref>) and was originally powered to an alternative outcome (the rate of
appearance of nonesterified FAs in the plasma). The power estimates from the pilot
study for the lipid endpoints measured here are given in supplementary Table I;
vascular data were not collected in the pilot study. Power to detect the main effects
of each agent on the primary lipid endpoints was &#x0003e;80% except for that of P-OM3 on
HDL-C and nonHDL-C. After initially qualifying for the study, subjects began a
6-week, diet-stabilization, dual-placebo, run-in phase (single-blind) in which
noncompliant subjects (i.e., &#x0003c;80% compliant) would have potentially been
identified and excluded (but none were). Those subjects completing the run-in phase
were randomly assigned using permuted blocks of four (with stratification for gender)
to 16 weeks of treatment to either dual placebo, extended-release niacin (ERN,
Niaspan, Abbott Labs, 2g/d), P-OM3 (Lovaza, GlaxoSmithKline Pharmaceuticals, 4g/d),
or the combination. To improve tolerance, ERN was titrated up over the first month by
adding 500 mg to the daily dose each week, to achieve the final 2 g/d (<xref ref-type="fig" rid="fig1">Fig. 1</xref>). All subjects (placebo and active) were
additionally asked to take aspirin (81 mg) prior to dinner to reduce flushing. In
order to improve blinding to ERN, the ERN placebos contained 50 mg rapid-release
niacin, which is enough to cause a mild flushing response. The study coordinator
assigned each treatment a letter (A&#x02013;D) and the biostatistician (J.V.P.)
generated the randomization schedule using an algorithm as described above. The
randomization schedule was then given to the staff at Sanford Clinic who enrolled
each participant and blindly assigned them to their treatment group. Subjects were
asked at 0, 8, and 16 weeks to report the previous week's flushing frequency and
intensity.</p><fig id="fig1" position="float"><label>Fig. 1.</label><caption><p>Flow diagram for the study. <sup>a</sup> safety (elevated CPK), inadequate IV
access; <sup>b</sup> rash, flushing; <sup>c</sup> inadequate IV access, time
constraints, migraine headache; <sup>d</sup> without index finger, problematic
RHI measurement at baseline; <sup>e</sup> error, subject should have been
excluded for high BMI.</p></caption><graphic xlink:href="2429fig1"/></fig><p>Lipid and vascular data collection took place at weeks 0 and 16. Subjects were asked
to fast for at least 8 h prior to each visit. Upon arriving at the dedicated study
room, the digital tonometry test (below) was administered first (&#x0223c;40 minutes)
followed by a blood draw for fasting lipids. Blood samples were drawn, plasma was
separated within 30 min, and samples were stored at &#x02212;70&#x000b0;C. Compliance to
treatment was assessed by pill count for both treatments and also (for P-OM3
treatment) by changes in the omega-3 index (OMX), which is the red blood cell (RBC)
FA weight percent of EPA and DHA. All subjects were &#x0003e;80% compliant by pill count.
The efficacy of blinding was assessed by a questionnaire after the study ended.</p></sec><sec><title>Plasma lipids</title><p>Plasma lipids and lipoproteins for study eligibility were measured using standard
hospital laboratory techniques, but for endpoint analysis (weeks 0 and 16), these
were assessed by ultracentrifugation-based Vertical Auto Profile (VAP; Atherotech,
Birmingham, AL). The correlation between the hospital and VAP methods for TG was 0.95
with a Deming regression slope (95% CI) = 1.02 (0.93, 1.12).</p></sec><sec><title>Digital tonometry</title><p>Reactive hyperemia index (RHI) was measured using an Endo-PAT2000 (Itamar Medical
Ltd., Caesarea, Israel). The Endo-PAT uses pneumatic probes placed on the
subject's fingertips to estimate pulsatile arterial volume and thus, changes in
blood flow. Probes were placed on symmetrical fingertips, generally the index finger
of each hand, a blood pressure cuff was loosely placed on the subject's dominant
arm, and a baseline reading was obtained. After 3 min, the cuff was inflated to
&#x0003e;300 mmHg to occlude blood flow for 5 min and then released. The RHI was obtained
by comparing the increase in digital pulse volume in the occluded arm to that in the
control arm per the method of Bonetti et al. (<xref ref-type="bibr" rid="bib21">21</xref>). The Framingham RHI (fRHI), a different approach to analyzing the data
than suggested by the manufacturer, was also determined (<xref ref-type="bibr" rid="bib22">22</xref>). The Endo-PAT2000 also estimates the augmentation index
(AI), which is a measure of arterial stiffness. It is defined as the proportion of
central pulse pressure due to the late systolic peak, which is in turn attributed to
the reflected pulse wave (<xref ref-type="bibr" rid="bib23">23</xref>). All Endo-PAT
measures were made by the same technician trained and certified by Itamar whose
specialists reviewed all Endo-PAT tracings to confirm the quality of the data.</p></sec><sec><title>RBC FAs</title><p>RBC FA composition was measured to document compliance with P-OM3 and was analyzed by
the HS-Omega-3 Index&#x000ae; methodology as previously described (<xref ref-type="bibr" rid="bib24">24</xref>). Fatty acid methyl esters were generated from erythrocytes
by acid <italic>trans</italic>-esterification and analyzed by gas chromatography
using a GC2010 Gas Chromatograph (Shimadzu, Columbia, MD) equipped with a SP2560,
100-m column (Supelco, Bellefonte, PA) using hydrogen as carrier gas. FAs were
identified by comparison with a standard mixture of FAs characteristic of
erythrocytes and expressed as a percentage of total identified FAs after response
factor correction.</p></sec><sec><title>Statistical methods</title><p>The changes in responses were modeled as the dependent variables, with adjustment for
baseline values due to chance differences related to the small sample size per group.
Because the power to detect interactions was low (&#x0003c;30%), the groups were tested
using a one-way ANCOVA with Dunnett adjustment for multiple comparisons to the
placebo group. Residuals were examined for normality and homogeneity, and a natural
log transformation was used as needed for improved model assumptions. The flushing
response was examined using McNemar's exact test from baseline to 8 and 16 weeks
for each treatment group. <italic>P</italic>-values &#x0003c; 0.05 were considered
statistically significant. Analyses were performed using SAS&#x000ae; software (version
9.2; SAS Institute Inc., Cary, NC) and JMP&#x000ae; software (version 8.0.2.2; SAS
Institute Inc., Cary, NC).</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>Participant flow and blinding</title><p>A diagram representing the flow of subjects through the study is given in <xref ref-type="fig" rid="fig1"><bold>Fig. 1</bold></xref>. At the completion of the
study, the majority (38; 63%) of subjects guessed they were taking ERN and 22 (37%)
guessed they were on active P-OM3 treatment, but there was no difference between the
guesses of subjects in the placebo or treatment groups (Fisher <italic>P</italic>
= 0.43). Thus, the subjects were effectively blinded to treatment.</p></sec><sec><title>Baseline characteristics</title><p>Subjects were recruited into the study between August 2007 and October 2008.
Seventy-one patients entered the single-blind placebo run-in phase. Three subjects
did not return for the baseline visit and seven were lost to follow-up. One subject
was included in the study but excluded from analysis when it was recognized that his
BMI was greater than the inclusion criterion. One subject had to be excluded from the
vascular endpoints due to prior surgery on one index finger that was not appreciated
at screening, which prevented him from being tested by EndoPat, and EndoPat data from
another was removed as an extreme outlier with problematic baseline measurement.
Thus, the final sample included 58 subjects for vascular endpoints and 60 for lipid
endpoints. Overall, the subjects demonstrated the characteristics of the metabolic
syndrome including high TG, low HDL-C, elevated BMI including waist circumferences of
97 (92, 105) for females and 107 (98, 112) for males, mild hypertension, and mild
hyperglycemia, indicating their condition was stable and did not change during the
run-in phase (<xref ref-type="table" rid="tbl1"><bold>Tables 1</bold></xref> and
<xref ref-type="table" rid="tbl2"><bold>2</bold></xref>). Except for nonHDL-C,
subjects were similar at baseline for primary endpoints (<xref ref-type="table" rid="tbl2">Table 2</xref>). The inclusion criteria used here were shown by
McLaughlin et al. (<xref ref-type="bibr" rid="bib25">25</xref>, <xref ref-type="bibr" rid="bib26">26</xref>) to be highly predictive of insulin resistance. The OMX
increased significantly in the P-OM3 groups indicating good compliance with treatment
(supplementary Fig. I).</p><table-wrap id="tbl1" position="float"><label>TABLE 1.</label><caption><p>Baseline characteristics by treatment group</p></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="1" colspan="1">Variable<xref ref-type="table-fn" rid="tblfn1"><italic><sup>a</sup></italic></xref></td><td align="center" rowspan="1" colspan="1">Dual Placebo (n = 15)</td><td align="center" rowspan="1" colspan="1">ERN (n = 15)</td><td align="center" rowspan="1" colspan="1">P-OM3 (n = 17)</td><td align="center" rowspan="1" colspan="1">Combination (n = 13)</td></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age (years)</td><td align="char" char="(" rowspan="1" colspan="1">45(39,65)<xref ref-type="table-fn" rid="tblfn2"><italic><sup>b</sup></italic></xref></td><td align="char" char="(" rowspan="1" colspan="1">49(41,56)</td><td align="char" char="(" rowspan="1" colspan="1">44(40,49)</td><td align="char" char="(" rowspan="1" colspan="1">48(44,54)</td></tr><tr><td rowspan="1" colspan="1">Sex male: n(%)</td><td align="char" char="(" rowspan="1" colspan="1">9(60%)</td><td align="char" char="(" rowspan="1" colspan="1">8(53%)</td><td align="char" char="(" rowspan="1" colspan="1">10(59%)</td><td align="char" char="(" rowspan="1" colspan="1">9(69%)</td></tr><tr><td rowspan="1" colspan="1">Current Smoker: n(%)</td><td align="char" char="(" rowspan="1" colspan="1">2(13%)</td><td align="char" char="(" rowspan="1" colspan="1">2(13%)</td><td align="char" char="(" rowspan="1" colspan="1">1(6%)</td><td align="char" char="(" rowspan="1" colspan="1">1(8%)</td></tr><tr><td rowspan="1" colspan="1">Resting Heart Rate (bpm)</td><td align="char" char="(" rowspan="1" colspan="1">68(60,76)</td><td align="char" char="(" rowspan="1" colspan="1">62(59,73)</td><td align="char" char="(" rowspan="1" colspan="1">72(63,78)</td><td align="char" char="(" rowspan="1" colspan="1">67(61,72)</td></tr><tr><td rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="char" char="(" rowspan="1" colspan="1">30(28,33)</td><td align="char" char="(" rowspan="1" colspan="1">33(28,36)</td><td align="char" char="(" rowspan="1" colspan="1">34(32,36)</td><td align="char" char="(" rowspan="1" colspan="1">31(30,35)</td></tr><tr><td rowspan="1" colspan="1">Systolic BP (mm Hg)</td><td align="char" char="(" rowspan="1" colspan="1">124(121,132)</td><td align="char" char="(" rowspan="1" colspan="1">141(124,144)</td><td align="char" char="(" rowspan="1" colspan="1">133(130,139)</td><td align="char" char="(" rowspan="1" colspan="1">131(128,139)</td></tr><tr><td rowspan="1" colspan="1">Diastolic BP (mm Hg)</td><td align="char" char="(" rowspan="1" colspan="1">81(76,87)</td><td align="char" char="(" rowspan="1" colspan="1">81(74,89)</td><td align="char" char="(" rowspan="1" colspan="1">86(79,90)</td><td align="char" char="(" rowspan="1" colspan="1">82(80,85)</td></tr><tr><td rowspan="1" colspan="1">Mean Arterial Pressure (mm Hg)</td><td align="char" char="(" rowspan="1" colspan="1">96(93,102)</td><td align="char" char="(" rowspan="1" colspan="1">97(94,108)</td><td align="char" char="(" rowspan="1" colspan="1">102(96,106)</td><td align="char" char="(" rowspan="1" colspan="1">100(95,103)</td></tr><tr><td rowspan="1" colspan="1">Glucose (mmol/L)</td><td align="char" char="." rowspan="1" colspan="1">5.5(4.9,5.8)<xref ref-type="table-fn" rid="tblfn3"><italic><sup>c</sup></italic></xref></td><td align="char" char="." rowspan="1" colspan="1">5.4(5.1,5.7)</td><td align="char" char="." rowspan="1" colspan="1">5.4(5.3,5.9)</td><td align="char" char="." rowspan="1" colspan="1">5.8(5.3,6.1)</td></tr><tr><td rowspan="1" colspan="1">Insulin (uU/ml)</td><td align="char" char="(" rowspan="1" colspan="1">15(<xref ref-type="bibr" rid="bib10">10</xref>,
<xref ref-type="bibr" rid="bib19">19</xref>)<xref ref-type="table-fn" rid="tblfn3"><italic><sup>c</sup></italic></xref></td><td align="char" char="(" rowspan="1" colspan="1">11(9,17)</td><td align="char" char="(" rowspan="1" colspan="1">11(5,16)</td><td align="char" char="(" rowspan="1" colspan="1">15(10,19)</td></tr><tr><td rowspan="1" colspan="1">Anti-hypertensive medication: n(%)</td><td align="char" char="(" rowspan="1" colspan="1">3(20%)</td><td align="char" char="(" rowspan="1" colspan="1">4(27%)</td><td align="char" char="(" rowspan="1" colspan="1">4(24%)</td><td align="char" char="(" rowspan="1" colspan="1">3(23%)</td></tr><tr><td rowspan="1" colspan="1">Statin use: n(%)</td><td align="char" char="(" rowspan="1" colspan="1">3(20%)</td><td align="char" char="(" rowspan="1" colspan="1">2(13%)</td><td align="char" char="(" rowspan="1" colspan="1">3(18%)</td><td align="char" char="(" rowspan="1" colspan="1">0(0%)</td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><label>a</label><p>Kruskal-Wallis test and Chi-squared test for continuous and categorical
data, respectively, all <italic>P</italic> &#x0003e; 0.05.</p></fn><fn id="tblfn2"><label>b</label><p>Median (Q1, Q3) unless otherwise indicated.</p></fn><fn id="tblfn3"><label>c</label><p>n = 13 (2 invalid assays).</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl2" position="float"><label>TABLE 2.</label><caption><p>Baseline values on lipid (N = 60) and vascular (N = 58) endpoints
by treatment group</p></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="1" colspan="1"/><td colspan="4" align="center" rowspan="1">Mean (SD)<hr/></td></tr><tr><td rowspan="1" colspan="1">[mg/dL] unless otherwise indicated</td><td rowspan="1" colspan="1">Dual Placebo</td><td align="center" rowspan="1" colspan="1">ERN</td><td align="center" rowspan="1" colspan="1">P-OM3</td><td align="center" rowspan="1" colspan="1">Combination</td></tr></thead><tbody><tr><td colspan="5" rowspan="1">&#x02003;Primary Endpoints</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Non HDL-Cholesterol (C)</td><td align="char" char="." rowspan="1" colspan="1">151 (24)</td><td align="center" rowspan="1" colspan="1">178<italic><sup>a</sup></italic> (49)</td><td align="char" char="." rowspan="1" colspan="1">144 (37)</td><td align="center" rowspan="1" colspan="1">177<italic><sup>a</sup></italic> (38)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;HDL-C</td><td align="char" char="." rowspan="1" colspan="1">40 (8)</td><td align="char" char="." rowspan="1" colspan="1">44 (10)</td><td align="char" char="." rowspan="1" colspan="1">43 (8)</td><td align="char" char="." rowspan="1" colspan="1">40 (8)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Triglyceride</td><td align="char" char="." rowspan="1" colspan="1">251 (174)</td><td align="char" char="." rowspan="1" colspan="1">196 (65)</td><td align="char" char="." rowspan="1" colspan="1">203 (72)</td><td align="char" char="." rowspan="1" colspan="1">228 (82)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Augmentation Index (units)</td><td align="char" char="." rowspan="1" colspan="1">2.6 (9.9)</td><td align="char" char="." rowspan="1" colspan="1">3.9 (9.0)</td><td align="char" char="." rowspan="1" colspan="1">3.8 (19.0)</td><td align="char" char="." rowspan="1" colspan="1">0.9 (8.5)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Reactive Hyperemia Index (units)</td><td align="char" char="." rowspan="1" colspan="1">1.99 (0.48)</td><td align="center" rowspan="1" colspan="1">1.55<italic><sup>b</sup></italic> (0.14)</td><td align="center" rowspan="1" colspan="1">1.55<italic><sup>b</sup></italic> (0.28)</td><td align="center" rowspan="1" colspan="1">1.58<italic><sup>b</sup></italic> (0.22)</td></tr><tr><td colspan="5" rowspan="1">Secondary Endpoints</td></tr><tr><td rowspan="1" colspan="1">&#x02003;TG:HDL</td><td align="char" char="." rowspan="1" colspan="1">6.8 (5.6)</td><td align="char" char="." rowspan="1" colspan="1">4.6 (1.6)</td><td align="char" char="." rowspan="1" colspan="1">4.9 (2.0)</td><td align="char" char="." rowspan="1" colspan="1">5.8 (2.0)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Total-C</td><td align="char" char="." rowspan="1" colspan="1">191 (28)</td><td align="center" rowspan="1" colspan="1">222<italic><sup>a,b</sup></italic> (54)</td><td align="char" char="." rowspan="1" colspan="1">186 (40)</td><td align="char" char="." rowspan="1" colspan="1">217 (41)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;LDL-C</td><td align="char" char="." rowspan="1" colspan="1">121 (23)</td><td align="center" rowspan="1" colspan="1">149<italic><sup>a,b</sup></italic> (44)</td><td align="char" char="." rowspan="1" colspan="1">114 (35)</td><td align="center" rowspan="1" colspan="1">141<italic><sup>a</sup></italic> (29)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;VLDL-C</td><td align="char" char="." rowspan="1" colspan="1">30 (11)</td><td align="char" char="." rowspan="1" colspan="1">29 (8)</td><td align="char" char="." rowspan="1" colspan="1">29 (9)</td><td align="char" char="." rowspan="1" colspan="1">36 (14)</td></tr><tr><td colspan="5" rowspan="1">VAP Lipoprotein Subfractions</td></tr><tr><td rowspan="1" colspan="1">&#x02003;HDL<sub>2</sub>-C</td><td align="char" char="." rowspan="1" colspan="1">7.2 (2.1)</td><td align="char" char="." rowspan="1" colspan="1">8.6 (2.7)</td><td align="char" char="." rowspan="1" colspan="1">8.2 (3.2)</td><td align="char" char="." rowspan="1" colspan="1">7.6 (2.7)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;HDL<sub>3</sub>-C</td><td align="char" char="." rowspan="1" colspan="1">32.3 (6.4)</td><td align="char" char="." rowspan="1" colspan="1">35.5 (7.0)</td><td align="char" char="." rowspan="1" colspan="1">34.5 (5.2)</td><td align="char" char="." rowspan="1" colspan="1">32.5 (6.0)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Small, Dense LDL-C (LDL<sub>3</sub>+LDL<sub>4</sub>)</td><td align="char" char="." rowspan="1" colspan="1">65.8 (17.2)</td><td align="char" char="." rowspan="1" colspan="1">72.7 (25.3)</td><td align="char" char="." rowspan="1" colspan="1">57.6 (22.6)</td><td align="char" char="." rowspan="1" colspan="1">78.5 (21.1)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Large Buoyant LDL-C (LDL<sub>1</sub>+LDL<sub>2</sub>)</td><td align="char" char="." rowspan="1" colspan="1">33.3 (15.6)</td><td align="center" rowspan="1" colspan="1">50.3<italic><sup>a,b,c</sup></italic> (24.3)</td><td align="char" char="." rowspan="1" colspan="1">33.8 (16.3)</td><td align="char" char="." rowspan="1" colspan="1">33.3 (10.5)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Large Buoyant LDL-C [%]</td><td align="char" char="." rowspan="1" colspan="1">33 (13)</td><td align="char" char="." rowspan="1" colspan="1">40 (15)</td><td align="char" char="." rowspan="1" colspan="1">37 (14)</td><td align="char" char="." rowspan="1" colspan="1">30 (8)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Time to Peak LDL-C [Secs]</td><td align="char" char="." rowspan="1" colspan="1">112 (5)</td><td align="char" char="." rowspan="1" colspan="1">114 (4)</td><td align="char" char="." rowspan="1" colspan="1">114 (7)</td><td align="char" char="." rowspan="1" colspan="1">111 (3)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Lp(a)-C</td><td align="char" char="." rowspan="1" colspan="1">7.3 (3.5)</td><td align="char" char="." rowspan="1" colspan="1">6.0 (3.4)</td><td align="char" char="." rowspan="1" colspan="1">4.9 (2.0)</td><td align="char" char="." rowspan="1" colspan="1">6.7 (3.8)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;IDL-C</td><td align="char" char="." rowspan="1" colspan="1">14.9 (8.6)</td><td align="char" char="." rowspan="1" colspan="1">20.1 (10.0)</td><td align="char" char="." rowspan="1" colspan="1">18.1 (10.2)</td><td align="char" char="." rowspan="1" colspan="1">22.5 (12.9)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Remnant Lipoproteins-C</td><td align="char" char="." rowspan="1" colspan="1">29.9 (11.9)</td><td align="char" char="." rowspan="1" colspan="1">35.1 (13.0)</td><td align="char" char="." rowspan="1" colspan="1">34.2 (14.6)</td><td align="char" char="." rowspan="1" colspan="1">41.8 (20.7)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;VLDL<sub>1+2</sub>-C</td><td align="char" char="." rowspan="1" colspan="1">15.1 (7.7)</td><td align="char" char="." rowspan="1" colspan="1">13.4 (5.4)</td><td align="char" char="." rowspan="1" colspan="1">13.3 (4.7)</td><td align="char" char="." rowspan="1" colspan="1">16.2 (6.5)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;VLDL<sub>3</sub>-C</td><td align="char" char="." rowspan="1" colspan="1">14.9 (4.1)</td><td align="char" char="." rowspan="1" colspan="1">15.0 (3.4)</td><td align="char" char="." rowspan="1" colspan="1">16.1 (5.2)</td><td align="char" char="." rowspan="1" colspan="1">19.2 (8.2)</td></tr></tbody></table><table-wrap-foot><fn><p>Different at baseline (p-value &#x0003c;0.05) compared with:
<italic><sup>a</sup></italic> P-OM3, <italic><sup>b</sup></italic> Dual
Placebo, <italic><sup>c</sup></italic> Combination group.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Effects on lipid and lipoprotein levels</title><p><xref ref-type="table" rid="tbl2">Table 2</xref> reports the baseline levels for
lipid and vascular endpoints along with details of the lipoprotein profile from the
VAP analysis. <xref ref-type="table" rid="tbl3"><bold>Table 3</bold></xref> reports
the treatment effects adjusted for baseline. In order to satisfy test assumptions, TG
and other indicated secondary endpoints were log-transformed, meaning that the
effects of treatment are best interpreted as proportional instead of absolute
changes; however, for simplicity, the absolute changes from baseline are also
indicated. ERN increased HDL-C by 5.4 mg/dl, and reduced TG by 21% (39 mg/dl) and
VLDL-C by 19% (5.3 mg/dl). The effect of P-OM3 was to reduce serum TG by 13% (26
mg/dl) and VLDL-C by 12% (3.5 mg/dl). Combination treatment increased HDL-C by 7.8
mg/dl, and decreased TG by 33% (72 mg/dl) and VLDL-C by 27% (8.9 mg/dl). The TG
reduction with combination treatment was greater than P-OM3 alone but was not greater
than ERN (<italic>P</italic> = 0.09).</p><table-wrap id="tbl3" position="float"><label>TABLE 3.</label><caption><p>Treatment effects on lipid (N = 60) and vascular (N = 58)
endpoints with ERN and P-OM3</p></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="1" colspan="1"/><td colspan="4" align="center" rowspan="1">Least Squares Mean Changes, Adjusted for
Baseline<xref ref-type="table-fn" rid="tblfn7"><italic><sup>a</sup></italic></xref><hr/></td></tr><tr><td rowspan="1" colspan="1">[mg/dL] unless otherwise indicated</td><td rowspan="1" colspan="1">Dual Placebo</td><td align="center" rowspan="1" colspan="1">ERN</td><td align="center" rowspan="1" colspan="1">P-OM3</td><td align="center" rowspan="1" colspan="1">Combination</td></tr></thead><tbody><tr><td colspan="5" rowspan="1">Primary Endpoints</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Non HDL-Cholesterol (C)</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;5.9</td><td align="char" char="*" rowspan="1" colspan="1">&#x02212;23*</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;11</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;7.3</td></tr><tr><td rowspan="1" colspan="1">&#x02003;HDL-C</td><td align="char" char="." rowspan="1" colspan="1">0.2</td><td align="char" char="." rowspan="1" colspan="1">5.4*</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;0.8</td><td align="char" char="." rowspan="1" colspan="1">7.8**</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Triglyceride<xref ref-type="table-fn" rid="tblfn8"><italic><sup>b</sup></italic></xref></td><td align="char" char=" " rowspan="1" colspan="1">19 (8.8%)</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;39 (&#x02212;21%)**</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;26 (&#x02212;13%)*</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;72
(&#x02212;33%)***c</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Augmentation Index (units)</td><td align="char" char="." rowspan="1" colspan="1">3.1</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;3.5*</td><td align="char" char="." rowspan="1" colspan="1">3.8</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;1.9</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Reactive Hyperemia Index (units)</td><td align="char" char="." rowspan="1" colspan="1">0.03</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;0.04</td><td align="char" char="." rowspan="1" colspan="1">0.08</td><td align="char" char="." rowspan="1" colspan="1">0.14</td></tr><tr><td colspan="5" char="." rowspan="1">Secondary Endpoints</td></tr><tr><td rowspan="1" colspan="1">&#x02003;TG:HDL<xref ref-type="table-fn" rid="tblfn8"><italic><sup>b</sup></italic></xref></td><td align="char" char="." rowspan="1" colspan="1">0.40 (8.2%)</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;1.51
(&#x02212;30%)***</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;0.47 (&#x02212;11%)</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;2.38
(&#x02212;44%)***</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Total-C</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;6.1</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;17</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;12</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;0.3</td></tr><tr><td rowspan="1" colspan="1">&#x02003;LDL-C</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;6.3</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;17</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;7.5</td><td align="char" char="." rowspan="1" colspan="1">2.9</td></tr><tr><td rowspan="1" colspan="1">&#x02003;VLDL-C<xref ref-type="table-fn" rid="tblfn8"><italic><sup>b</sup></italic></xref></td><td align="char" char="." rowspan="1" colspan="1">0.8 (2.8%)</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;5.3 (&#x02212;19%)**</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;3.5 (&#x02212;12%)*</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;8.9
(&#x02212;27%)***c</td></tr><tr><td colspan="5" char="." rowspan="1">VAP Lipoprotein Subfractions</td></tr><tr><td rowspan="1" colspan="1">&#x02003;HDL<sub>2</sub>-C</td><td align="char" char="." rowspan="1" colspan="1">0.4</td><td align="char" char="." rowspan="1" colspan="1">1.7</td><td align="char" char="." rowspan="1" colspan="1">0.3</td><td align="char" char="." rowspan="1" colspan="1">3.3**</td></tr><tr><td rowspan="1" colspan="1">&#x02003;HDL<sub>3</sub>-C</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;0.3</td><td align="char" char="." rowspan="1" colspan="1">3.8*</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;1.1</td><td align="char" char="." rowspan="1" colspan="1">4.4**</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Small, Dense LDL-C (LDL<sub>3</sub>+LDL<sub>4</sub>)</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;4.7</td><td align="char" char="*" rowspan="1" colspan="1">&#x02212;18*</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;6.7</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;13</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Large, Buoyant LDL-C (LDL<sub>1</sub>+LDL<sub>2</sub>)</td><td align="char" char="." rowspan="1" colspan="1">0.2</td><td align="char" char="." rowspan="1" colspan="1">2.9</td><td align="char" char="." rowspan="1" colspan="1">2.3</td><td align="char" char="*" rowspan="1" colspan="1">20**</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Large, Buoyant LDL-C [%]</td><td align="char" char="." rowspan="1" colspan="1">0.9</td><td align="char" char="." rowspan="1" colspan="1">9.2</td><td align="char" char="." rowspan="1" colspan="1">2.2</td><td align="char" char="*" rowspan="1" colspan="1">16**</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Time to Peak LDL-C [Secs]</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;0.3</td><td align="char" char="." rowspan="1" colspan="1">2.4*</td><td align="char" char="." rowspan="1" colspan="1">0.6</td><td align="char" char="." rowspan="1" colspan="1">4.5***</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Lp(a)-C<xref ref-type="table-fn" rid="tblfn8"><italic><sup>b</sup></italic></xref></td><td align="char" char="." rowspan="1" colspan="1">1.3 (20%)</td><td align="char" char="." rowspan="1" colspan="1">0.8 (16%)</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;0.1 (&#x02212;1.1%)</td><td align="char" char="." rowspan="1" colspan="1">1.3 (22%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;IDL-C</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;2.1</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;4.5</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;3.6</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;1.4</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Remnant Lipoproteins-C</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;2.3</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;7.2</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;5.4</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;5.6</td></tr><tr><td rowspan="1" colspan="1">&#x02003;VLDL<sub>1+2</sub>-C<xref ref-type="table-fn" rid="tblfn8"><italic><sup>b</sup></italic></xref></td><td align="char" char="." rowspan="1" colspan="1">0.8 (5.6%)</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;2.4 (&#x02212;19%)**</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;1.7 (&#x02212;14%)*</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;4.8
(&#x02212;32%)***<italic><sup>c,d</sup></italic></td></tr><tr><td rowspan="1" colspan="1">&#x02003;VLDL<sub>3</sub>-C<xref ref-type="table-fn" rid="tblfn8"><italic><sup>b</sup></italic></xref></td><td align="char" char="." rowspan="1" colspan="1">0.1 (1.0%)</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;2.5 (&#x02212;17%)**</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;1.6 (&#x02212;10%)</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;4.0
(&#x02212;22%)***</td></tr></tbody></table><table-wrap-foot><fn id="tblfn5"><label>a</label><p>Dunnett adjusted <italic>p</italic>-value compared with dual placebo,
* <italic>P</italic> &#x0003c; 0.05, ** <italic>P</italic>
&#x0003c; 0.01, *** <italic>P</italic> &#x0003c; 0.001.</p></fn><fn id="tblfn6"><label>b</label><p>Natural-logarithm transformed for improved normality and homoscedasticity of
residuals. The % change effect (shown in parenthesis) was converted back
into original units by multiplying it by the groups&#x02019; geometric mean at
week 0.</p></fn><fn id="tblfn7"><label>c</label><p>Different than P-OM3 group change, <italic>P</italic> &#x0003c; 0.05.</p></fn><fn id="tblfn8"><label>d</label><p>Different than ERN group change, <italic>P</italic> &#x0003c; 0.05.</p></fn></table-wrap-foot></table-wrap><p>Combination treatment had the greatest impact on lipoprotein subfractions, where
improvements in particle density were observed. Subjects on combination therapy and
on ERN had increased levels of small, dense HDL<sub>3</sub>; however, only subjects
on combination therapy received the benefit of increased larger, buoyant
HDL<sub>2</sub>. VLDL<sub>1+2</sub>-C decreased more with combination
treatment that with either monotherapy. Similar improvements were observed for LDL,
which were shifted toward a greater proportion of large, buoyant particles reflected
by an increased LDL<sub>1</sub> + LDL<sub>2</sub> in subjects on combination
therapy, and time to peak LDL in the combination group.</p></sec><sec><title>Effects on vascular function</title><p><xref ref-type="table" rid="tbl3">Table 3</xref> also shows the adjusted treatment
effects on vascular function. ERN significantly reduced the AI, a marker of vascular
stiffness, by 3.5 units. No effect on this measure was observed in either P-OM3 or
combination treatments. No significant effect of either agent (singly or combined)
was observed on endothelial function measured by RHI or on blood pressure (data not
shown). The effects of treatment on flushing are shown in supplementary Table II. The
expected flushing effect of niacin was noted with combination therapy at the 8 and 16
week visits; P-OM3 did not prevent it.</p></sec><sec><title>Effects on endpoints as a function of changes in RBC n-3 FAs</title><p>Robust biomarkers of tissue incorporation exist for P-OM3 therapy (i.e., OMX). Use of
this marker allowed us to (potentially) reduce some heterogeneity in response to this
agent. To determine the relations between change in major endpoints and n-3 FA
incorporation into tissues, we repeated the analyses using the OMX<sub>final</sub> /
OMX<sub>initial</sub> (i.e., the percent changes in the OMX) instead of P-OM3
treatment assignment (<xref ref-type="fig" rid="fig2"><bold>Fig. 2</bold></xref>). TG
reductions were significantly related to the increase in OMX (similar results for EPA
or DHA alone were also seen), and the model fit was improved using this metric. This
demonstrates that the TG response to therapy was better explained by the change in
tissue n-3 FA levels than it was by group assignment.</p><fig id="fig2" position="float"><label>Fig. 2.</label><caption><p>Changes in triglycerides (TG) (including 95% CI bands) as a function of the
change in omega-3 index (OMX) levels in the two groups that received P-OM3. For
each group, the extent of TG lowering was in proportion to the relative
increase in OMX (P = 02). The greater TG lowering with combination
therapy is reflected in the step function between treatment groups (P =
0.001). The line at <italic>y</italic>=1 represents identity, or no
change from baseline. The results are shown as the least-squares fit of the
semi-log line, note the log-scale of the <italic>y</italic>&#x0200a;-axis. Using
the ratios of DHA and of EPA (as final/baseline) gave similar results. N
= 30; because there was no change in OMX or TG levels for subjects on
placebo P-OM3, they were not included in the analysis.</p></caption><graphic xlink:href="2429fig2"/></fig></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>We compared the single and combined effects of ERN and P-OM3 on the dyslipidemia and
vascular dysfunction characteristic of the metabolic syndrome. We found that ERN broadly
improved dyslipidemia and vascular stiffness whereas P-OM3 improved
hypertriglyceridemia. The combination had additive effects on TG beyond that of P-OM3
alone but not beyond ERN alone. Combination therapy was the only group that had an
increase in large, buoyant HDL. Combination treatment did not affect LDL-C levels but it
did shift the LDL profile away from the more atherogenic, small, dense LDL particles
toward the less atherogenic, large, buoyant particles. Considering all lipid and
lipoprotein classes, subjects on combination therapy had the greatest improvements.</p><p>ERN had a profound effect across the lipoprotein spectrum. It increased HDL to a similar
extent to that reported in the ARBITER 6-HALTS trial (<xref ref-type="bibr" rid="bib10">10</xref>) where the increase was associated with reduced carotid intima-media
thickness. Whereas ERN therapy alone increased HDL<sub>3</sub>, combination therapy
increased the abundance of the more atheroprotective HDL<sub>2</sub> particles. This is
of particular interest because it suggests a qualitative improvement in HDL that is
present only with both treatments.</p><p>One endpoint for which combination therapy was not better than the individual agents was
LDL-C (and nonHDL-C and total-C). For these endpoints, the addition of P-OM3 essentially
cancelled the LDL-C lowering effect of ERN. Increased LDL-C has been observed previously
with interventions that improve TG metabolism (<xref ref-type="bibr" rid="bib27">27</xref>); however, it has not been previously reported for this combination and
needs to be confirmed. Regardless, we did not find that LDL-C was increased, and we
found a shift in buoyancy that is consistent with less atherosclerotic risk (<xref ref-type="bibr" rid="bib28">28</xref>). Kuvin et al. (<xref ref-type="bibr" rid="bib29">29</xref>) report ERN increased the size and buoyancy of LDL,
theoretically rendering them less atherogenic. This effect was large enough among
subjects on combination therapy that it likely explains unchanged LDL-C. Although these
endpoints are not components of metabolic syndrome dyslipidemia, they are well
established components of cardiovascular risk.</p><p>Finally, ERN decreased TG and VLDL-C by roughly 20%. The 12% reduction in these markers
by P-OM3 is on the low end of that observed in previous studies in hypertriglyceridemic
patients (<xref ref-type="bibr" rid="bib30">30</xref>), and it is smaller than the
effect reported in more severe hypertriglyceridemia (&#x02212;45%) (<xref ref-type="bibr" rid="bib14">14</xref>) or in mild hypertriglyceridemia of statin-treated subjects who
were not selected for metabolic syndrome (&#x02212;29%) (<xref ref-type="bibr" rid="bib13">13</xref>).</p><p>The primary finding on vascular endpoints was a reduction by ERN in the AI, which is a
measure of vascular stiffness. Given the time allowed for adjusting to ERN (4 months),
the gap between the time when the subjects took their final dose of ERN, and when AI was
measured (several hours), it does not seem likely that the change in AI was an acute
response to niacin-induced vasodilation; however, this cannot be ruled out.</p><p>Using the change in OMX (or EPA or DHA) instead of group assignment, the relations
between TG and P-OM3 treatment were more clearly discerned. Subjects having the greatest
increase in RBC n-3 FA levels also had the largest improvements in lipids, suggesting
that tissue n-3 FA levels are more closely related to physiological parameters than
group assignment. If true, titrating to a target tissue level may be more effective than
giving a fixed dose (<xref ref-type="bibr" rid="bib31">31</xref>).</p><sec><title>Limitations</title><p>The sample size was relatively small and treatment duration short
(i.e<italic>.</italic>, months instead of years). Accordingly, although the study
was well-powered to detect main effects on most lipid endpoints, there was little
power to detect interactions. In other words, we were unlikely to detect effects of
combination therapy beyond those that were simply additive. We also note that
although we did not detect an effect of P-OM3 on nonHDL-C, our study was not powered
to detect this endpoint and this should be considered in light of findings from
larger studies (<xref ref-type="bibr" rid="bib13">13</xref>). Despite randomization,
baseline values for some endpoints (nonHDL-C and LDL-C in the P-OM3 group and RHI in
the placebo group) were not uniform, due again to the small sample size. These
imbalances may have confounded the results despite adjustment for baseline
values.</p><p>In conclusion, combination therapy with ERN and POM-3 produced additive effects on
serum TG and on HDL and LDL size and buoyancy. These changes are consistent with a
decrease in risk for coronary events; however, further prospective trials are
necessary to confirm this.</p></sec></sec>
<sec sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material id="PMC_1" content-type="local-data">
<caption>
<title>Supplemental Tables and Figure</title>
</caption>
<media mimetype="text" mime-subtype="html" xlink:href="supp_53_11_2429__index.html"/>
<media xlink:role="associated-file" mimetype="application" mime-subtype="pdf"
xlink:href="supp_P022392_FONIA-JLR-submit-3-supplemental.pdf"/>
</supplementary-material>
</sec>
</body><back><ack><p>The authors acknowledge the assistance of Brenda Collison-Schmidt, Kristi Fillaus, Karla
Riley, and Marilyn Ruhlman for their excellent study coordination and execution of study
protocols.</p></ack><fn-group><fn fn-type="abbr" id="gloss1"><p><def-list><title>Abbreviations:</title><def-item><term>AI</term><def><p>augmentation index</p></def></def-item><def-item><term>BMI</term><def><p>body mass indexCHD, coronary heart disease</p></def></def-item><def-item><term>ERN</term><def><p>extended-release niacin</p></def></def-item><def-item><term>HLD-C</term><def><p>HDL cholesterol</p></def></def-item><def-item><term>OMX</term><def><p>omega-3 index</p></def></def-item><def-item><term>P-OM3</term><def><p>prescription omega-3 acid ethyl-esters</p></def></def-item><def-item><term>RBC</term><def><p>red blood cell</p></def></def-item><def-item><term>RHI</term><def><p>reactive hyperemia index</p></def></def-item><def-item><term>TG</term><def><p>triglyceride</p></def></def-item><def-item><term>VAP</term><def><p>Vertical Auto Profile</p></def></def-item></def-list></p></fn><fn fn-type="financial-disclosure"><p>This study was funded by the National Institutes of Health (5 R01 DK061486). Abbott
(Niaspan) and GlaxoSmithKline (Lovaza) provided the drugs used in this study. Its
contents are solely the responsibility of the authors and do not necessarily
represent the official views of the National Institutes of Health or other granting
agencies. G.C.S. received research support from GlaxoSmithKline. G.C.S. and W.S.H.
received speakership honoraria from GlaxoSmithKline.</p></fn><fn id="fn1" fn-type="supplementary-material"><label>[S]</label><p>The online version of this article (available at <ext-link ext-link-type="uri" xlink:href="http://www.jlr.org">http://www.jlr.org</ext-link>) contains supplementary data in the form of two
tables and one figure.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="bib1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ford</surname><given-names>E. S.</given-names></name><name><surname>Giles</surname><given-names>W. H.</given-names></name><name><surname>Dietz</surname><given-names>W. H.</given-names></name></person-group>
<year>2002</year>
<article-title>Prevalence of the metabolic
syndrome among US adults: findings from the third National Health and Nutrition
Examination Survey</article-title>. <source>JAMA.</source>
<volume>287</volume>: <fpage>356</fpage>&#x02013;<lpage>359</lpage><pub-id pub-id-type="pmid">11790215</pub-id></mixed-citation></ref><ref id="bib2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milionis</surname><given-names>H. J.</given-names></name><name><surname>Rizos</surname><given-names>E.</given-names></name><name><surname>Goudevenos</surname><given-names>J.</given-names></name><name><surname>Seferiadis</surname><given-names>K.</given-names></name><name><surname>Mikhailidis</surname><given-names>D. P.</given-names></name><name><surname>Elisaf</surname><given-names>M. S.</given-names></name></person-group>
<year>2005</year>
<article-title>Components of the metabolic
syndrome and risk for first-ever acute ischemic nonembolic stroke in elderly
subjects</article-title>. <source>Stroke.</source>
<volume>36</volume>: <fpage>1372</fpage>&#x02013;<lpage>1376</lpage><pub-id pub-id-type="pmid">15933255</pub-id></mixed-citation></ref><ref id="bib3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiao</surname><given-names>Q.</given-names></name></person-group>
<year>2006</year>
<article-title>Comparison of different definitions of the
metabolic syndrome in relation to cardiovascular mortality in European men and
women</article-title>. <source>Diabetologia.</source>
<volume>49</volume>: <fpage>2837</fpage>&#x02013;<lpage>2846</lpage><pub-id pub-id-type="pmid">17021922</pub-id></mixed-citation></ref><ref id="bib4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katzmarzyk</surname><given-names>P. T.</given-names></name><name><surname>Janssen</surname><given-names>I.</given-names></name><name><surname>Ross</surname><given-names>R.</given-names></name><name><surname>Church</surname><given-names>T. S.</given-names></name><name><surname>Blair</surname><given-names>S. N.</given-names></name></person-group>
<year>2006</year>
<article-title>The importance of waist
circumference in the definition of metabolic syndrome: prospective analyses of
mortality in men</article-title>. <source>Diabetes Care.</source>
<volume>29</volume>: <fpage>404</fpage>&#x02013;<lpage>409</lpage><pub-id pub-id-type="pmid">16443895</pub-id></mixed-citation></ref><ref id="bib5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brillante</surname><given-names>D. G.</given-names></name><name><surname>O'Sullivan</surname><given-names>A. J.</given-names></name><name><surname>Howes</surname><given-names>L. G.</given-names></name></person-group>
<year>2009</year>
<article-title>Arterial stiffness in insulin
resistance: the role of nitric oxide and angiotensin II receptors</article-title>.
<source>Vasc. Health Risk Manag.</source>
<volume>5</volume>: <fpage>73</fpage>&#x02013;<lpage>78</lpage><pub-id pub-id-type="pmid">19436651</pub-id></mixed-citation></ref><ref id="bib6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gazi</surname><given-names>I.</given-names></name><name><surname>Tsimihodimos</surname><given-names>V.</given-names></name><name><surname>Filippatos</surname><given-names>T.</given-names></name><name><surname>Bairaktari</surname><given-names>E.</given-names></name><name><surname>Tselepis</surname><given-names>A. D.</given-names></name><name><surname>Elisaf</surname><given-names>M.</given-names></name></person-group>
<year>2006</year>
<article-title>Concentration and relative
distribution of low-density lipoprotein subfractions in patients with metabolic
syndrome defined according to the National Cholesterol Education Program
criteria</article-title>. <source>Metabolism.</source>
<volume>55</volume>: <fpage>885</fpage>&#x02013;<lpage>891</lpage><pub-id pub-id-type="pmid">16784959</pub-id></mixed-citation></ref><ref id="bib7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ageno</surname><given-names>W.</given-names></name><name><surname>Prandoni</surname><given-names>P.</given-names></name><name><surname>Romualdi</surname><given-names>E.</given-names></name><name><surname>Ghirarduzzi</surname><given-names>A.</given-names></name><name><surname>Dentali</surname><given-names>F.</given-names></name><name><surname>Pesavento</surname><given-names>R.</given-names></name><name><surname>Crowther</surname><given-names>M.</given-names></name><name><surname>Venco</surname><given-names>A.</given-names></name></person-group>
<year>2006</year>
<article-title>The metabolic syndrome and the
risk of venous thrombosis: a case-control study</article-title>. <source>J.
Thromb. Haemost.</source>
<volume>4</volume>: <fpage>1914</fpage>&#x02013;<lpage>1918</lpage><pub-id pub-id-type="pmid">16848878</pub-id></mixed-citation></ref><ref id="bib8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanko</surname><given-names>L. B.</given-names></name><name><surname>Bagger</surname><given-names>Y. Z.</given-names></name><name><surname>Qin</surname><given-names>G.</given-names></name><name><surname>Alexandersen</surname><given-names>P.</given-names></name><name><surname>Larsen</surname><given-names>P. J.</given-names></name><name><surname>Christiansen</surname><given-names>C.</given-names></name></person-group>
<year>2005</year>
<article-title>Enlarged waist combined with
elevated triglycerides is a strong predictor of accelerated atherogenesis and
related cardiovascular mortality in postmenopausal women</article-title>.
<source>Circulation.</source>
<volume>111</volume>: <fpage>1883</fpage>&#x02013;<lpage>1890</lpage><pub-id pub-id-type="pmid">15837940</pub-id></mixed-citation></ref><ref id="bib9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guyton</surname><given-names>J. R.</given-names></name><name><surname>Goldberg</surname><given-names>A. C.</given-names></name><name><surname>Kreisberg</surname><given-names>R. A.</given-names></name><name><surname>Sprecher</surname><given-names>D. L.</given-names></name><name><surname>Superko</surname><given-names>H. R.</given-names></name><name><surname>O'Connor</surname><given-names>C. M.</given-names></name></person-group>
<year>1998</year>
<article-title>Effectiveness of once-nightly
dosing of extended-release niacin alone and in combination for
hypercholesterolemia</article-title>. <source>Am. J. Cardiol.</source>
<volume>82</volume>: <fpage>737</fpage>&#x02013;<lpage>743</lpage><pub-id pub-id-type="pmid">9761083</pub-id></mixed-citation></ref><ref id="bib10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villines</surname><given-names>T. C.</given-names></name><name><surname>Stanek</surname><given-names>E. J.</given-names></name><name><surname>Devine</surname><given-names>P. J.</given-names></name><name><surname>Turco</surname><given-names>M.</given-names></name><name><surname>Miller</surname><given-names>M.</given-names></name><name><surname>Weissman</surname><given-names>N. J.</given-names></name><name><surname>Griffen</surname><given-names>L.</given-names></name><name><surname>Taylor</surname><given-names>A. J.</given-names></name></person-group>
<year>2010</year>
<article-title>The ARBITER 6-HALTS Trial
(Arterial Biology for the Investigation of the Treatment Effects of Reducing
Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results
and the impact of medication adherence, dose, and treatment
duration</article-title>. <source>J. Am. Coll. Cardiol.</source>
<volume>55</volume>: <fpage>2721</fpage>&#x02013;<lpage>2726</lpage><pub-id pub-id-type="pmid">20399059</pub-id></mixed-citation></ref><ref id="bib11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Canner</surname><given-names>P. L.</given-names></name><name><surname>Berge</surname><given-names>K. G.</given-names></name><name><surname>Wenger</surname><given-names>N. K.</given-names></name><name><surname>Stamler</surname><given-names>J.</given-names></name><name><surname>Friedman</surname><given-names>L.</given-names></name><name><surname>Prineas</surname><given-names>R. J.</given-names></name><name><surname>Friedewald</surname><given-names>W.</given-names></name></person-group>
<year>1986</year>
<article-title>Fifteen year mortality in Coronary
Drug Project patients: long-term benefit with niacin</article-title>. <source>J.
Am. Coll. Cardiol.</source>
<volume>8</volume>: <fpage>1245</fpage>&#x02013;<lpage>1255</lpage><pub-id pub-id-type="pmid">3782631</pub-id></mixed-citation></ref><ref id="bib12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boden</surname><given-names>W. E.</given-names></name><name><surname>Probstfield</surname><given-names>J. L.</given-names></name><name><surname>Anderson</surname><given-names>T.</given-names></name><name><surname>Chaitman</surname><given-names>B. R.</given-names></name><name><surname>Desvignes-Nickens</surname><given-names>P.</given-names></name><name><surname>Koprowicz</surname><given-names>K.</given-names></name><name><surname>McBride</surname><given-names>R.</given-names></name><name><surname>Teo</surname><given-names>K.</given-names></name><name><surname>Weintraub</surname><given-names>W.</given-names></name></person-group>
<year>2011</year>
<article-title>Niacin in patients with low HDL
cholesterol levels receiving intensive statin therapy</article-title>. <source>N.
Engl. J. Med.</source>
<volume>365</volume>: <fpage>2255</fpage>&#x02013;<lpage>2267</lpage><pub-id pub-id-type="pmid">22085343</pub-id></mixed-citation></ref><ref id="bib13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidson</surname><given-names>M. H.</given-names></name><name><surname>Stein</surname><given-names>E. A.</given-names></name><name><surname>Bays</surname><given-names>H. E.</given-names></name><name><surname>Maki</surname><given-names>K. C.</given-names></name><name><surname>Doyle</surname><given-names>R. T.</given-names></name><name><surname>Shalwitz</surname><given-names>R. A.</given-names></name><name><surname>Ballantyne</surname><given-names>C. M.</given-names></name><name><surname>Ginsberg</surname><given-names>H. N.</given-names></name></person-group>
<year>2007</year>
<article-title>Efficacy and tolerability of
adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in
hypertriglyceridemic patients: an 8-week, randomized, double-blind,
placebo-controlled study</article-title>. <source>Clin. Ther.</source>
<volume>29</volume>: <fpage>1354</fpage>&#x02013;<lpage>1367</lpage><pub-id pub-id-type="pmid">17825687</pub-id></mixed-citation></ref><ref id="bib14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>W. S.</given-names></name><name><surname>Ginsberg</surname><given-names>H. N.</given-names></name><name><surname>Arunakul</surname><given-names>N.</given-names></name><name><surname>Shachter</surname><given-names>N. S.</given-names></name><name><surname>Windsor</surname><given-names>S. L.</given-names></name><name><surname>Adams</surname><given-names>M.</given-names></name><name><surname>Berglund</surname><given-names>L.</given-names></name><name><surname>Osmundsen</surname><given-names>K.</given-names></name></person-group>
<year>1997</year>
<article-title>Safety and efficacy of Omacor in
severe hypertriglyceridemia</article-title>. <source>J. Cardiovasc. Risk.</source>
<volume>4</volume>: <fpage>385</fpage>&#x02013;<lpage>391</lpage><pub-id pub-id-type="pmid">9865671</pub-id></mixed-citation></ref><ref id="bib15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marchioli</surname><given-names>R.</given-names></name><name><surname>Barzi</surname><given-names>F.</given-names></name><name><surname>Bomba</surname><given-names>E.</given-names></name><name><surname>Chieffo</surname><given-names>C.</given-names></name><name><surname>Di Gregorio</surname><given-names>D.</given-names></name><name><surname>Di Mascio</surname><given-names>R.</given-names></name><name><surname>Franzosi</surname><given-names>M. G.</given-names></name><name><surname>Geraci</surname><given-names>E.</given-names></name><name><surname>Levantesi</surname><given-names>G.</given-names></name><name><surname>Maggioni</surname><given-names>A. P.</given-names></name><etal/></person-group>
<year>2002</year>
<article-title>Early protection against sudden
death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course
analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza
nell'Infarto Miocardico (GISSI)-Prevenzione</article-title>.
<source>Circulation.</source>
<volume>105</volume>: <fpage>1897</fpage>&#x02013;<lpage>1903</lpage><pub-id pub-id-type="pmid">11997274</pub-id></mixed-citation></ref><ref id="bib16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marchioli</surname><given-names>R.</given-names></name><name><surname>Levantesi</surname><given-names>G.</given-names></name><name><surname>Silletta</surname><given-names>M. G.</given-names></name><name><surname>Barlera</surname><given-names>S.</given-names></name><name><surname>Bernardinangeli</surname><given-names>M.</given-names></name><name><surname>Carbonieri</surname><given-names>E.</given-names></name><name><surname>Cosmi</surname><given-names>F.</given-names></name><name><surname>Franzosi</surname><given-names>M. G.</given-names></name><name><surname>Latini</surname><given-names>R.</given-names></name><name><surname>Lucci</surname><given-names>D.</given-names></name><etal/></person-group>
<year>2009</year>
<article-title>Effect of n-3 polyunsaturated
fatty acids and rosuvastatin in patients with heart failure: results of the
GISSI-HF trial</article-title>. <source>Expert Rev. Cardiovasc. Ther.</source>
<volume>7</volume>: <fpage>735</fpage>&#x02013;<lpage>748</lpage><pub-id pub-id-type="pmid">19589110</pub-id></mixed-citation></ref><ref id="bib17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yokoyama</surname><given-names>M.</given-names></name><name><surname>Origasa</surname><given-names>H.</given-names></name><name><surname>Matsuzaki</surname><given-names>M.</given-names></name><name><surname>Matsuzawa</surname><given-names>Y.</given-names></name><name><surname>Saito</surname><given-names>Y.</given-names></name><name><surname>Ishikawa</surname><given-names>Y.</given-names></name><name><surname>Oikawa</surname><given-names>S.</given-names></name><name><surname>Sasaki</surname><given-names>J.</given-names></name><name><surname>Hishida</surname><given-names>H.</given-names></name><name><surname>Itakura</surname><given-names>H.</given-names></name><etal/></person-group>
<year>2007</year>
<article-title>Effects of eicosapentaenoic acid
on major coronary events in hypercholesterolaemic patients (JELIS): a randomised
open-label, blinded endpoint analysis</article-title>. <source>Lancet.</source>
<volume>369</volume>: <fpage>1090</fpage>&#x02013;<lpage>1098</lpage><pub-id pub-id-type="pmid">17398308</pub-id></mixed-citation></ref><ref id="bib18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dangardt</surname><given-names>F.</given-names></name><name><surname>Osika</surname><given-names>W.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Nilsson</surname><given-names>U.</given-names></name><name><surname>Gan</surname><given-names>L. M.</given-names></name><name><surname>Gronowitz</surname><given-names>E.</given-names></name><name><surname>Strandvik</surname><given-names>B.</given-names></name><name><surname>Friberg</surname><given-names>P.</given-names></name></person-group>
<year>2010</year>
<article-title>Omega-3 fatty acid supplementation
improves vascular function and reduces inflammation in obese
adolescents</article-title>. <source>Atherosclerosis.</source>
<volume>212</volume>: <fpage>580</fpage>&#x02013;<lpage>585</lpage><pub-id pub-id-type="pmid">20727522</pub-id></mixed-citation></ref><ref id="bib19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamilton</surname><given-names>S. J.</given-names></name><name><surname>Chew</surname><given-names>G. T.</given-names></name><name><surname>Davis</surname><given-names>T. M.</given-names></name><name><surname>Watts</surname><given-names>G. F.</given-names></name></person-group>
<year>2010</year>
<article-title>Niacin improves small artery
vasodilatory function and compliance in statin-treated type 2 diabetic
patients</article-title>. <source>Diab. Vasc. Dis. Res.</source>
<volume>7</volume>: <fpage>296</fpage>&#x02013;<lpage>299</lpage><pub-id pub-id-type="pmid">20667937</pub-id></mixed-citation></ref><ref id="bib20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isley</surname><given-names>W. L.</given-names></name><name><surname>Miles</surname><given-names>J. M.</given-names></name><name><surname>Harris</surname><given-names>W. S.</given-names></name></person-group>
<year>2007</year>
<article-title>Pilot study of combined therapy
with &#x003c9;-3 fatty acids and niacin in atherogenic dyslipidemia</article-title>.
<source>J. Clin. Lipidol.</source>
<volume>1</volume>: <fpage>211</fpage>&#x02013;<lpage>217</lpage><pub-id pub-id-type="pmid">21291683</pub-id></mixed-citation></ref><ref id="bib21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonetti</surname><given-names>P. O.</given-names></name><name><surname>Pumper</surname><given-names>G. M.</given-names></name><name><surname>Higano</surname><given-names>S. T.</given-names></name><name><surname>Holmes</surname><given-names>D. R.</given-names><suffix>Jr</suffix></name><name><surname>Kuvin</surname><given-names>J. T.</given-names></name><name><surname>Lerman</surname><given-names>A.</given-names></name></person-group>
<year>2004</year>
<article-title>Noninvasive identification of
patients with early coronary atherosclerosis by assessment of digital reactive
hyperemia</article-title>. <source>J. Am. Coll. Cardiol.</source>
<volume>44</volume>: <fpage>2137</fpage>&#x02013;<lpage>2141</lpage><pub-id pub-id-type="pmid">15582310</pub-id></mixed-citation></ref><ref id="bib22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamburg</surname><given-names>N. M.</given-names></name><name><surname>Keyes</surname><given-names>M. J.</given-names></name><name><surname>Larson</surname><given-names>M. G.</given-names></name><name><surname>Vasan</surname><given-names>R. S.</given-names></name><name><surname>Schnabel</surname><given-names>R.</given-names></name><name><surname>Pryde</surname><given-names>M. M.</given-names></name><name><surname>Mitchell</surname><given-names>G. F.</given-names></name><name><surname>Sheffy</surname><given-names>J.</given-names></name><name><surname>Vita</surname><given-names>J. A.</given-names></name><name><surname>Benjamin</surname><given-names>E. J.</given-names></name></person-group>
<year>2008</year>
<article-title>Cross-sectional relations of
digital vascular function to cardiovascular risk factors in the Framingham Heart
Study</article-title>. <source>Circulation.</source>
<volume>117</volume>: <fpage>2467</fpage>&#x02013;<lpage>2474</lpage><pub-id pub-id-type="pmid">18458169</pub-id></mixed-citation></ref><ref id="bib23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yasmin</surname></name><name><surname>Brown</surname><given-names>M. J.</given-names></name></person-group>
<year>1999</year>
<comment>Similarities and differences between
augmentation index and pulse wave velocity in the assessment of arterial
stiffness. <italic>QJM</italic> 92: 595&#x02013;600</comment></mixed-citation></ref><ref id="bib24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>W. S.</given-names></name><name><surname>Von Schacky</surname><given-names>C.</given-names></name></person-group>
<year>2004</year>
<article-title>The Omega-3 Index: a new risk
factor for death from coronary heart disease?</article-title>
<source>Prev. Med.</source>
<volume>39</volume>: <fpage>212</fpage>&#x02013;<lpage>220</lpage><pub-id pub-id-type="pmid">15208005</pub-id></mixed-citation></ref><ref id="bib25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLaughlin</surname><given-names>T.</given-names></name><name><surname>Abbasi</surname><given-names>F.</given-names></name><name><surname>Cheal</surname><given-names>K.</given-names></name><name><surname>Chu</surname><given-names>J.</given-names></name><name><surname>Lamendola</surname><given-names>C.</given-names></name><name><surname>Reaven</surname><given-names>G.</given-names></name></person-group>
<year>2003</year>
<article-title>Use of metabolic markers to
identify overweight individuals who are insulin resistant</article-title>.
<source>Ann. Intern. Med.</source>
<volume>139</volume>: <fpage>802</fpage>&#x02013;<lpage>809</lpage><pub-id pub-id-type="pmid">14623617</pub-id></mixed-citation></ref><ref id="bib26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLaughlin</surname><given-names>T.</given-names></name><name><surname>Reaven</surname><given-names>G.</given-names></name><name><surname>Abbasi</surname><given-names>F.</given-names></name><name><surname>Lamendola</surname><given-names>C.</given-names></name><name><surname>Saad</surname><given-names>M.</given-names></name><name><surname>Waters</surname><given-names>D.</given-names></name><name><surname>Simon</surname><given-names>J.</given-names></name><name><surname>Krauss</surname><given-names>R. M.</given-names></name></person-group>
<year>2005</year>
<article-title>Is there a simple way to identify
insulin-resistant individuals at increased risk of cardiovascular
disease?</article-title>
<source>Am. J. Cardiol.</source>
<volume>96</volume>: <fpage>399</fpage>&#x02013;<lpage>404</lpage><pub-id pub-id-type="pmid">16054467</pub-id></mixed-citation></ref><ref id="bib27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dachet</surname><given-names>C.</given-names></name><name><surname>Cavallero</surname><given-names>E.</given-names></name><name><surname>Martin</surname><given-names>C.</given-names></name><name><surname>Girardot</surname><given-names>G.</given-names></name><name><surname>Jacotot</surname><given-names>B.</given-names></name></person-group>
<year>1995</year>
<article-title>Effect of gemfibrozil on the
concentration and composition of very low density and low density lipoprotein
subfractions in hypertriglyceridemic patients</article-title>.
<source>Atherosclerosis.</source>
<volume>113</volume>: <fpage>1</fpage>&#x02013;<lpage>9</lpage><pub-id pub-id-type="pmid">7755644</pub-id></mixed-citation></ref><ref id="bib28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Superko</surname><given-names>H. R.</given-names></name><name><surname>Gadesam</surname><given-names>R. R.</given-names></name></person-group>
<year>2008</year>
<article-title>Is it LDL particle size or number
that correlates with risk for cardiovascular disease?</article-title>
<source>Curr. Atheroscler. Rep.</source>
<volume>10</volume>: <fpage>377</fpage>&#x02013;<lpage>385</lpage><pub-id pub-id-type="pmid">18706278</pub-id></mixed-citation></ref><ref id="bib29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuvin</surname><given-names>J. T.</given-names></name><name><surname>Dave</surname><given-names>D. M.</given-names></name><name><surname>Sliney</surname><given-names>K. A.</given-names></name><name><surname>Mooney</surname><given-names>P.</given-names></name><name><surname>Patel</surname><given-names>A. R.</given-names></name><name><surname>Kimmelstiel</surname><given-names>C. D.</given-names></name><name><surname>Karas</surname><given-names>R. H.</given-names></name></person-group>
<year>2006</year>
<article-title>Effects of extended-release niacin
on lipoprotein particle size, distribution, and inflammatory markers in patients
with coronary artery disease</article-title>. <source>Am. J. Cardiol.</source>
<volume>98</volume>: <fpage>743</fpage>&#x02013;<lpage>745</lpage><pub-id pub-id-type="pmid">16950175</pub-id></mixed-citation></ref><ref id="bib30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>W. S.</given-names></name></person-group>
<year>1996</year>
<article-title>n-3 fatty acids and lipoproteins: comparison of
results from human and animal studies</article-title>. <source>Lipids.</source>
<volume>31</volume>: <fpage>243</fpage>&#x02013;<lpage>252</lpage><pub-id pub-id-type="pmid">8900453</pub-id></mixed-citation></ref><ref id="bib31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Von Schacky</surname><given-names>C.</given-names></name></person-group>
<year>2010</year>
<article-title>Omega-3 fatty acids vs. cardiac disease&#x02013;the
contribution of the omega-3 index</article-title>. <source>Cell Mol Biol
(Noisy-le-grand).</source>
<volume>56</volume>: <fpage>93</fpage>&#x02013;<lpage>101</lpage><pub-id pub-id-type="pmid">20196973</pub-id></mixed-citation></ref></ref-list></back></article>